CVE:COV

Covalon Technologies Competitors

C$1.55

+0.05 (+3.33 %)

(As of 04/20/2021 11:06 AM ET)

Add

Compare

Today's Range

C$1.50

Now: C$1.55▼

C$1.55

50-Day Range

C$1.32

MA: C$1.46▼

C$1.76

52-Week Range

C$0.70

Now: C$1.55▼

C$1.99

Volume985 shs

Average Volume5,820 shs

Market CapitalizationC$40.02 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Covalon Technologies (CVE:COV) Vs. IPA, HBP, ACST, NVH, MBX, and PDP

Should you be buying COV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Covalon Technologies, including ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), Acasti Pharma (ACST), Novoheart (NVH), Microbix Biosystems (MBX), and Pediapharm (PDP).

Covalon Technologies vs. ImmunoPrecise Antibodies Stock

Covalon Technologies (CVE:COV) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Covalon Technologies	0	0	0	0	N/A
ImmunoPrecise Antibodies	0	0	0	0	N/A

Earnings and Valuation

This table compares Covalon Technologies and ImmunoPrecise Antibodies' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	C$23.84 million	1.68	C$-6,144,922.00	C($0.24)	-6.51
ImmunoPrecise Antibodies	C$17.18 million	13.08	C$-4,082,906.00	C($0.21)	-55.05

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Covalon Technologies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Summary

ImmunoPrecise Antibodies beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.

Covalon Technologies vs. Helix BioPharma Stock

Covalon Technologies (CVE:COV) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Helix BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Covalon Technologies	0	0	0	0	N/A
Helix BioPharma	0	0	0	0	N/A

Earnings and Valuation

This table compares Covalon Technologies and Helix BioPharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	C$23.84 million	1.68	C$-6,144,922.00	C($0.24)	-6.51
Helix BioPharma	N/A	N/A	N/A	C($0.06)	-16.00

Helix BioPharma has lower revenue, but higher earnings than Covalon Technologies. Helix BioPharma is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Helix BioPharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	N/A	N/A	N/A
Helix BioPharma	N/A	N/A	N/A

Summary

Covalon Technologies beats Helix BioPharma on 2 of the 3 factors compared between the two stocks.

Covalon Technologies vs. Acasti Pharma Stock

Covalon Technologies (CVE:COV) and Acasti Pharma (CVE:ACST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Acasti Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Covalon Technologies	0	0	0	0	N/A
Acasti Pharma	0	0	0	0	N/A

Earnings and Valuation

This table compares Covalon Technologies and Acasti Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	C$23.84 million	1.68	C$-6,144,922.00	C($0.24)	-6.51
Acasti Pharma	C$81,000.00	1,334.13	C$6.80 million	C$0.03	15.88

Acasti Pharma has lower revenue, but higher earnings than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Acasti Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	N/A	N/A	N/A
Acasti Pharma	N/A	N/A	N/A

Summary

Acasti Pharma beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.

Covalon Technologies vs. Novoheart Stock

Covalon Technologies (CVE:COV) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Novoheart, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Covalon Technologies	0	0	0	0	N/A
Novoheart	0	0	0	0	N/A

Earnings and Valuation

This table compares Covalon Technologies and Novoheart's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	C$23.84 million	1.68	C$-6,144,922.00	C($0.24)	-6.51
Novoheart	C$423,500.00	236.08	C$-7,168,358.00	C($0.04)	-13.95

Covalon Technologies has higher revenue and earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Novoheart's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	N/A	N/A	N/A
Novoheart	N/A	N/A	N/A

Summary

Covalon Technologies beats Novoheart on 3 of the 5 factors compared between the two stocks.

Covalon Technologies vs. Microbix Biosystems Stock

Covalon Technologies (CVE:COV) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Microbix Biosystems, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Covalon Technologies	0	0	0	0	N/A
Microbix Biosystems	0	0	0	0	N/A

Earnings and Valuation

This table compares Covalon Technologies and Microbix Biosystems' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	C$23.84 million	1.68	C$-6,144,922.00	C($0.24)	-6.51
Microbix Biosystems	C$11.64 million	5.55	C$-5,581,797.00	C($0.05)	-11.57

Microbix Biosystems has lower revenue, but higher earnings than Covalon Technologies. Microbix Biosystems is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Microbix Biosystems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	N/A	N/A	N/A
Microbix Biosystems	N/A	N/A	N/A

Summary

Microbix Biosystems beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.

Covalon Technologies vs. Pediapharm Stock

Covalon Technologies (CVE:COV) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Covalon Technologies and Pediapharm, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Covalon Technologies	0	0	0	0	N/A
Pediapharm	0	0	0	0	N/A

Valuation and Earnings

This table compares Covalon Technologies and Pediapharm's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Covalon Technologies	C$23.84 million	1.68	C$-6,144,922.00	C($0.24)	-6.51
Pediapharm	C$11.16 million	5.95	C$-16,147,162.00	C($0.07)	-4.11

Covalon Technologies has higher revenue and earnings than Pediapharm. Covalon Technologies is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Pediapharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Covalon Technologies	N/A	N/A	N/A
Pediapharm	N/A	N/A	N/A

Summary

Pediapharm beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.